The Effect of Sodium Butyrate Enemas Compared with Placebo on Disease Activity, Endoscopic Scores, and Histological and Inflammatory Parameters in Inflammatory Bowel Diseases: A Systematic Review of Randomised Controlled Trials

Jamka, Małgorzata; Kokot, Marta; Kaczmarek, Nina; Bermagambetova, Saule; Nowak, Jan; Walkowiak, Jarosław

doi:10.1159/000512952

Cited by 21 publications

(17 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 136 In a systematic review and meta-analysis of eight randomized clinical trials on a total of 227 patients with UC, Jamka et al reported that current limited evidence does not support the use of butyrate enemas in UC. 137 Due to inconsistencies in the response of butyrate therapy, perhaps at some degree due to variability in dosages, duration and a standardization of the formula, current applicability of butyrate in IBD is considered as an add-on supplementary therapy at best. 121 , 138 One area in which butyrate has shown more consistent effectiveness is in cases of diversion colitis, a post-surgical manifestation when a part of colon is out of continuity and butyrate depletion is thought to be the major factor for driving inflammation.…”

Section: Clinical Significance For Select Gi Diseasesmentioning

confidence: 99%

The Immunomodulatory Functions of Butyrate

Siddiqui¹,

Cresci²

2021

JIR

188

View full text Add to dashboard Cite

Section: Clinical Significance For Select Gi Diseasesmentioning

confidence: 99%

The Immunomodulatory Functions of Butyrate

Siddiqui¹,

Cresci²

2021

JIR

188

View full text Add to dashboard Cite

“…As butter contains butyrate, a type of fatty acid that is also produced by gut bacteria and has been demonstrated to inhibit inflammation by enhancing NF-kB and feeding colonocytes [145], one might argue that butter is beneficial for patients with IBD. However, a recent systematic review demonstrated that sodium butyrate enemas have limited effect on histological and inflammatory parameters in patients with IBD [146]. Animal studies showed that diets high in saturated milk fat promoted Bacteroidetes and decrease Firmicutes in Il10−/−mice [147].…”

Section: Buttermentioning

confidence: 99%

Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID)

Campmans-Kuijpers

Dijkstra

2021

Nutrients

View full text Add to dashboard Cite

Diet plays a pivotal role in the onset and course of inflammatory bowel disease (IBD). Patients are keen to know what to eat to reduce symptoms and flares, but dietary guidelines are lacking. To advice patients, an overview of the current evidence on food (group) level is needed. This narrative review studies the effects of food (groups) on the onset and course of IBD and if not available the effects in healthy subjects or animal and in vitro IBD models. Based on this evidence the Groningen anti-inflammatory diet (GrAID) was designed and compared on food (group) level to other existing IBD diets. Although on several foods conflicting results were found, this review provides patients a good overview. Based on this evidence, the GrAID consists of lean meat, eggs, fish, plain dairy (such as milk, yoghurt, kefir and hard cheeses), fruit, vegetables, legumes, wheat, coffee, tea and honey. Red meat, other dairy products and sugar should be limited. Canned and processed foods, alcohol and sweetened beverages should be avoided. This comprehensive review focuses on anti-inflammatory properties of foods providing IBD patients with the best evidence on which foods they should eat or avoid to reduce flares. This was used to design the GrAID.

show abstract

“…In addition, none of the histological changes following enemas reached statistical significance. A recent review by Jamka et al [63] compiled all IBD clinical trials to date using butyrate enemas, including 8 studies and 227 patients with UC. They concluded that butyrate enema treatment in UC does not result in a significant improvement in disease activity index, endoscopic, or histological scores [63].…”

Section: Metabolomics Of the Gut Microbiome In Ibdmentioning

confidence: 99%

“…A recent review by Jamka et al [63] compiled all IBD clinical trials to date using butyrate enemas, including 8 studies and 227 patients with UC. They concluded that butyrate enema treatment in UC does not result in a significant improvement in disease activity index, endoscopic, or histological scores [63]. The prominent reason suggested to explain this result is that the short half-life of butyrate in vivo prevents its efficacy, and efforts to alter the chemical structure, micro-encapsulate it, or improve dietary production by fiber are ongoing.…”

Section: Metabolomics Of the Gut Microbiome In Ibdmentioning

confidence: 99%

Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease

Bekkers

Stojkovic

Kaiko

2021

IJMS

View full text Add to dashboard Cite

The intestinal microbiota is a complex community that consists of an ecosystem with a dynamic interplay between bacteria, fungi, archaea, and viruses. Recent advances in model systems have revealed that the gut microbiome is critical for maintaining homeostasis through metabolic digestive function, immune regulation, and intestinal barrier integrity. Taxonomic shifts in the intestinal microbiota are strongly correlated with a multitude of human diseases, including inflammatory bowel disease (IBD). However, many of these studies have been descriptive, and thus the understanding of the cause and effect relationship often remains unclear. Using non-human experimental model systems such as gnotobiotic mice, probiotic mono-colonization, or prebiotic supplementation, researchers have defined numerous species-level functions of the intestinal microbiota that have produced therapeutic candidates for IBD. Despite these advances, the molecular mechanisms responsible for the function of much of the microbiota and the interplay with host cellular processes remain areas of tremendous research potential. In particular, future research will need to unlock the functional molecular units of the microbiota in order to utilize this untapped resource of bioactive molecules for therapy. This review will highlight the advances and remaining challenges of microbiota-based functional studies and therapeutic discovery, specifically in IBD. One of the limiting factors for reviewing this topic is the nascent development of this area with information on some drug candidates still under early commercial development. We will also highlight the current and evolving strategies, including in the biotech industry, used for the discovery of microbiota-derived bioactive molecules in health and disease.

show abstract

The Effect of Sodium Butyrate Enemas Compared with Placebo on Disease Activity, Endoscopic Scores, and Histological and Inflammatory Parameters in Inflammatory Bowel Diseases: A Systematic Review of Randomised Controlled Trials

Cited by 21 publications

References 46 publications

The Immunomodulatory Functions of Butyrate

The Immunomodulatory Functions of Butyrate

Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID)

Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease

Contact Info

Product

Resources

About